These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27246168)

  • 1. Dramatic regression of macular and peripheral retinoschisis with dorzolamide 2 % in X-linked retinoschisis: a case report.
    Sadaka A; Sisk RA
    J Med Case Rep; 2016 Jun; 10(1):142. PubMed ID: 27246168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of mid-peripheral schisis in x-linked retinoschisis with the use of dorzolamide.
    Collison FT; Genead MA; Fishman GA; Stone EM
    Ophthalmic Genet; 2014 Jun; 35(2):125-7. PubMed ID: 23514609
    [No Abstract]   [Full Text] [Related]  

  • 3. Paradoxical Anatomic Response to Topical Carbonic Anhydrase Inhibitor in X-linked Retinoschisis.
    Menke B; Walters A; Payne JF
    Ophthalmic Surg Lasers Imaging Retina; 2018 Feb; 49(2):142-144. PubMed ID: 29443366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of response to treatment with dorzolamide in X-linked retinoschisis to the mechanism of functional loss in retinoschisin.
    Walia S; Fishman GA; Molday RS; Dyka FM; Kumar NM; Ehlinger MA; Stone EM
    Am J Ophthalmol; 2009 Jan; 147(1):111-115.e1. PubMed ID: 18834580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic response to topical dorzolamide in X-linked retinoschisis.
    Thangavel R; Surve A; Azad S; Kumar V
    Indian J Ophthalmol; 2020 Jul; 68(7):1466-1467. PubMed ID: 32587200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo imaging reveals novel aspects of retinal disease progression in Rs1h(-/Y) mice but no therapeutic effect of carbonic anhydrase inhibition.
    Zhour A; Bolz S; Grimm C; Willmann G; Schatz A; Weber BH; Zrenner E; Fischer MD
    Vet Ophthalmol; 2012 Sep; 15 Suppl 2():123-33. PubMed ID: 22672048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of topical and systemic carbonic anhydrase in the treatment of chromosome X-linked retinoschisis.
    Rocha Cabrera P; Pareja Ríos AC; Cordovés Dorta L; Mantolán Sarmiento C; Serrano García MA
    Arch Soc Esp Oftalmol; 2014 Aug; 89(8):320-3. PubMed ID: 24269421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolution of optic disc pit-associated macular retinoschisis after topical carbonic anhydrase inhibitor treatment: Report of a case.
    Al-Moujahed A; Callaway NF; Vail D; Ludwig CA; Ji MH; Moshfeghi DM
    Eur J Ophthalmol; 2021 May; 31(3):NP25-NP28. PubMed ID: 32019335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of dorzolamide for patients with X-linked retinoschisis.
    Apushkin MA; Fishman GA
    Retina; 2006 Sep; 26(7):741-5. PubMed ID: 16963845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STELLATE NONHEREDITARY IDIOPATHIC FOVEOMACULAR RETINOSCHISIS: RESPONSE TO TOPICAL DORZOLAMIDE THERAPY.
    Ajlan RS; Hammamji KS
    Retin Cases Brief Rep; 2019; 13(4):364-366. PubMed ID: 28557864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis.
    Genead MA; Fishman GA; Walia S
    Arch Ophthalmol; 2010 Feb; 128(2):190-7. PubMed ID: 20142541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide.
    Iannaccone A; Fung KH; Eyestone ME; Stone EM
    Am J Ophthalmol; 2009 Feb; 147(2):307-312.e2. PubMed ID: 18835469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbonic anhydrase inhibitors limit complications in X-linked retinoschisis.
    Wey S; Brill DA; Miraldi Utz V; Sisk RA
    Front Med (Lausanne); 2023; 10():1281068. PubMed ID: 38020097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TOPICAL CARBONIC ANHYDRASE INHIBITORS IN THE LONG-TERM TREATMENT OF JUVENILE X-LINKED RETINOSCHISIS.
    Schmitt MA; Wang K; DeBenedictis MJ; Traboulsi EI
    Retina; 2022 Nov; 42(11):2176-2183. PubMed ID: 35982512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral giant macular schisis in a case of Goldmann-Favre syndrome.
    Chawla R; Banerjee M
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31558488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of topical dorzolamide for patients with X-linked juvenile retinoschisis: case report.
    Bastos AL; Freitas Bde P; Villas Boas O; Ramiro AC
    Arq Bras Oftalmol; 2008; 71(2):286-90. PubMed ID: 18516436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystoid macular lesions are resistant to topical dorzolamide treatment in enhanced S-cone syndrome child.
    Bušić M; Bjeloš M; Bosnar D; Ramić S; Bušić I
    Doc Ophthalmol; 2016 Feb; 132(1):67-73. PubMed ID: 26803827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and diagnosis of retinoschisis and schisis detachments using spectral domain optical coherence tomography.
    Jalalizadeh RA; Smith BT
    Graefes Arch Clin Exp Ophthalmol; 2023 Feb; 261(2):375-380. PubMed ID: 35984486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outer layer breaks and asymptomatic schisis detachment: clinical considerations.
    Malagola R; Contestabile MT; Villani GM; De Santis EM; Recupero SM
    Ophthalmic Surg Lasers; 2002; 33(5):368-72. PubMed ID: 12358289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocriplasmin for foveal schisis in X-linked retinoschisis.
    Patel A; Morse L
    Retin Cases Brief Rep; 2015; 9(3):248-51. PubMed ID: 26002140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.